Akèy › Melanom › Massachusetts
Etid klinik pou Melanom nan Massachusetts
29 etid pou Melanom ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07751042BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05136196Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07492680DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- Massachusetts General Hospital Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07288112Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT04899908A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07070232Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Massachusetts General Hospital Cancer Center, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT05779423Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- ak 1 plis
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06150664A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
Ap rekriteFaz 1/2
6 Months – 17 Years · Tout sèks · Mizajou Jul 6, 2026 · NCT02332668Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT05225428Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Massachusetts General Hospital, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07015190A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Dana Farber, Boston
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT06624644A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Massachusetts General Hospital, Boston
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Apr 2, 2026 · NCT06581406Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT05549297ACTengine® IMA203 Combined With mRNA-4203
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT06946225Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Jan 5, 2026 · NCT05428007SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT04370587A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2025 · NCT05669430Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT04787042Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 18, 2024 · NCT05280314Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.